References
FIGURE LEGENDS
FIGURE 1: MTHFR genotype effect on maximum tolerated C-MTX and HDMTX
clearance times. Maximum tolerated C-MTX (A) and HDMTX clearance times
for each patient were plotted according to specific MTHFR genotype. *, p
< 0.05; n.s., not significant. MTX, methotrexate.
FIGURE 2: Oral MTX and 6-MP during maintenance therapy. Maximum
tolerated doses of oral MTX (A) and oral 6-MP (B) were obtained for each
patient and plotted according to specific MTHFR genotype. (C & D) 6-MP
metabolite data for 6-TG and 6-MMP were obtained from patient records
while they were on 100% recommended protocol dosing and compare to
maximum tolerated oral 6-MP dose (C) or maximum tolerated oral dose (D).
*, p < 0.05; **, p < 0.01; n.s., not significant:
MTX, methotrexate; 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine; 6-MMP,
6-methylmercaptopurine; RBC, red blood cell.
FIGURE 3: Toxicities triggering the assessment of MTHFR genotype status.
The causal reason for sending MTHFR genetic testing for each patient was
obtained from the medical record and broadly categorized into groups
listed in figure. Note: for patients who had no documentation for
sending of MTHFR genetic testing, classification group unknown was used.